ProMPT 2 reaches full recruitment target
The Trial Team are delighted to announce that ProMPT 2 has now reached its full recruitment target of 240 patients randomised into the study.
ProMPT 2 is an NIHR-funded randomised controlled trial investigating post-operative complications for patients undergoing heart surgery, specifically, coronary artery bypass graft (CABG) surgery.
Research suggests that propofol, widely used as a general anaesthetic, may have a protective effect on the heart. Cardioplegia solution is given to patients to keep the heart still and provide nutrients during heart surgery. This study aims to investigate the efficacy of adding different doses of propofol or saline to the cardioplegia solution during CABG surgery to reduce post-operative complications.
The study team had anticipated needing an additional 6-months to finish recruitment, but with consistent recruitment over the summer of 2022, the team ended up only needing an additional 2-months extension. Special thanks go out to the cardiac research team at University Hospitals Bristol and Weston NHS Foundation Trust for their amazing efforts in recruiting 90% of ProMPT 2 patients! We could not have reached this milestone without you.
With recruitment now complete, the study enters a 12-month follow-up period, with data cleaning already in progress. The overall study end date is 31/03/2024.
This project (EME Project: 15/180/55) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.
International Clinical Trials Methodology Conference (ICTMC) – October 2022
The ICTMC is the leading international platform for researchers and practitioners to present the very latest in trials methodology research. The meeting also offers valuable networking and training opportunities. A number of colleagues attended the meeting, presenting posters, abstracts and lightning talks.